- Anti Covid drug 2-DG launched by Defence Minister and Health Minister
- 2-DG developed by DRDO in collaboration with Dr. Reddy’s Lab
- Drug to reduce average recovery time by 2.5 days and oxygen demand by 40%
- Today is a historic day in our fight against COVID: Dr. Harsh Vardhan
- Union Health Minister lauds efforts of scientists for developing first indigenous anti COVID drug
Minister of Defence, Shri Rajnath Singh and Minister of Health and Family Welfare, Dr. Harsh Vardhan today jointly launched the new COVID drug 2-DG at DRDO Bhawan. The anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), along with Dr Reddy’s Laboratories (DRL), Hyderabad.
One box each of the sachets of the drug was handed over to Dr Randeep Guleria. Director, All India Institute of Medical Sciences (AIIMS), New Delhi and Lt Gen Shri Sunil Kant of Armed Forces Medical Services (AFMS).
Speaking at the launch Dr Harsh Vardhan remarked that today is a historic day in our fight against COVID and congratulated the scientific community and DRDO for their patience and perseverance for developing first indigenous medicine. He said that the drug has the potential to become a game changer in our response against COVID pandemic as it reduces the dependence of patients on oxygen administration and has the potential of getting absorbed differentially and in a selected manner. In the COVID infected cells, it inhibits virus synthesis and energy production for the process.
Joining the event virtually, Chairman, DRL Shri Kallam Satish Reddy said, “Dr. Reddy’s is glad to have partnered with DRDO and INMAS in the development of 2-DG. This is a re-affirmation of our company’s efforts to address COVID through a host of therapeutics and vaccine.”
